Enter Details

Comment on stories, receive email newsletters & alerts.

This is your permanent identity for Business Insider Australia
Your email must be valid for account activation
Minimum of 8 standard keyboard characters


Email newsletters but will contain a brief summary of our top stories and news alerts.

Forgotten Password

Enter Details

Back to log in

This company's shares are on a tear after it discovered a way to help pigs with diarrhoea

The Pig Racing and Diving show at the Royal Melbourne Show. Scott Barbour/Getty Images

Shares in Anatara Lifesciences are on a tear after the developer of therapies for pig diarrhoea signed an exclusive license option agreement with Zoetis, a leading global animal health company.

A short time ago, the shares were up 8.5% to at $1.40, about three times the price of a year ago.

Under the agreement, Zoetis has the exclusive global right to evaluate potential applications of Detach, Anatara’s non-antibiotic treatment for diarrhoea, for veterinary use in production animals.

Anatara retains rights to the Australian and New Zealand markets.

Diarrhoea is a problem for pig farms, with sick pigs losing condition and piglets dying. Traditionally antibiotics are used to treat this. Australia processes almost 5 million pigs a year in an industry worth $1 billion.

Anatara raised $9 million in a share placement in July last year so the company could push into Europe, the US and Asia earlier than forecast.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at